Zhen Zeng

5PUBLICATIONS
15CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 10, 2026
S-phase targeted treatment triggers caspase-dependent lytic immunogenic cell death with pyroptotic features in cancers.

|Jun 13, 2025
Checkpoint Kinase 1 Inhibitor Combined with Low Dose Hydroxyurea Promotes ATM-Activated NF-κB-Dependent Pro-Inflammatory Chemokine Expression in Melanomas.

Nicole Lisa Li-Ann Goh, Nur Jannah Abdul Rahim, Rituparna Bhatt

|Aug 24, 2023
Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas.

Zhen Zeng, Hung Long Ngo, Martina Proctor

|Apr 30, 2021
IFN-γ Critically Enables the Intratumoural Infiltration of CXCR3+ CD8+ T Cells to Drive Squamous Cell Carcinoma Regression.

Zhen Zeng, Margaret Veitch, Gabrielle A Kelly

|Apr 03, 2021
Investigating T Cell Immunity in Cancer: Achievements and Prospects.

Zhen Zeng, Hui Yi Chew, Jazmina G Cruz

Pageof 1

Frequent Collaborators

3 joint publications

Brian Gabrielli

2 joint publications

James W Wells

1 joint publications

Graham R Leggatt

1 joint publications

Zewen K Tuong